Albireo Pharma Inc Kapitalrendite
Was ist das Kapitalrendite von Albireo Pharma Inc?
Kapitalrendite von Albireo Pharma Inc ist -97.59%
Was ist die Definition von Kapitalrendite?
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Kapitalrendite von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc
Was macht Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Unternehmen mit kapitalrendite ähnlich Albireo Pharma Inc
- TCR2 Therapeutics hat Kapitalrendite von -97.81%
- Lianhua Supermarket Co hat Kapitalrendite von -97.68%
- ZEN Graphene Solutions hat Kapitalrendite von -97.65%
- Edison Nation hat Kapitalrendite von -97.62%
- Sierra Oncology Inc hat Kapitalrendite von -97.61%
- VIVO Cannabis hat Kapitalrendite von -97.59%
- Albireo Pharma Inc hat Kapitalrendite von -97.59%
- Goldcliff Resource hat Kapitalrendite von -97.54%
- iMedia Brands hat Kapitalrendite von -97.45%
- OXE Marine AB (publ) hat Kapitalrendite von -97.41%
- KalVista Pharmaceuticals Inc hat Kapitalrendite von -97.37%
- Pieris Pharmaceuticals Inc hat Kapitalrendite von -97.28%
- Alès e SA hat Kapitalrendite von -97.21%